Education
About Us
Working with TipRanks
Follow Us
Benitec Biopharma Ltd (BNTC)
NASDAQ:BNTC
BNTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.75 - $16.90
Previous CloseN/A
Volume10.71K
Average Volume (3M)43.66K
Market Cap
$328.56M
Enterprise Value$30.13M
Total Cash (Recent Filing)$20.37M
Total Debt (Recent Filing)$423.00K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
May 19, 2025EPS Estimate
-0.35Last Dividend Ex-Date
Jun 01, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding23,451,475
10 Day Avg. Volume72,680
30 Day Avg. Volume43,655
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit278.98
Enterprise Value/Ebitda-1.26
Forecast
1Y Price Target
$25.33Price Target Upside80.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Benitec Biopharma News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBB-301 low-dose regimen continues to demonstrate promise, with increasing durability of response at latest update.
Regulatory ApprovalAnalysts see a straightforward path to an approvable profile for BB-301 in oculopharyngeal muscular dystrophy, where current treatment options are limited and invasive.
Safety ProfileNo severe adverse events have been reported in any study subjects, suggesting a strong safety record for BB-301.
Bears Say
Data RobustnessThe small number of patients in the trial limits the robustness of the data, and further evidence is needed to confirm a dose-response relationship.
EarningsBenitec Biopharma recorded a net loss of $0.33 per share vs. a forecast of a net loss of $0.27 per share.
Financial PerformanceResearch and Development expenses were higher than both the analyst's and consensus estimates.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTC FAQ
What was Benitec Biopharma Ltd’s price range in the past 12 months?
Benitec Biopharma Ltd lowest stock price was $4.75 and its highest was $16.90 in the past 12 months.
What is Benitec Biopharma Ltd’s market cap?
Benitec Biopharma Ltd’s market cap is $328.56M.
When is Benitec Biopharma Ltd’s upcoming earnings report date?
Benitec Biopharma Ltd’s upcoming earnings report date is May 19, 2025 which is in 52 days.
How were Benitec Biopharma Ltd’s earnings last quarter?
Benitec Biopharma Ltd released its earnings results on Feb 14, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.776 by $0.446.
Is Benitec Biopharma Ltd overvalued?
According to Wall Street analysts Benitec Biopharma Ltd’s price is currently Undervalued.
Does Benitec Biopharma Ltd pay dividends?
Benitec Biopharma Ltd pays a Notavailable dividend of $0.51 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma Ltd dividends here
What is Benitec Biopharma Ltd’s EPS estimate?
Benitec Biopharma Ltd’s EPS estimate is -0.35.
How many shares outstanding does Benitec Biopharma Ltd have?
Benitec Biopharma Ltd has 23,451,475 shares outstanding.
What happened to Benitec Biopharma Ltd’s price movement after its last earnings report?
Benitec Biopharma Ltd reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.776. Following the earnings report the stock price went up 15.979%.
Which hedge fund is a major shareholder of Benitec Biopharma Ltd?
Currently, no hedge funds are holding shares in BNTC
---
Benitec Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.33 (80.80% Upside)
$25.33 (80.80% Upside)
Blogger Sentiment
Bullish
BNTC Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $527.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
182.45%
12-Months-Change
Fundamentals
Return on Equity
-46.85%
Trailing 12-Months
Asset Growth
270.29%
Trailing 12-Months
Company Description
Benitec Biopharma Ltd
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
---
BNTC Stock 12 Month Forecast
Average Price Target
$25.33
▲(80.80% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Bluebird Bio
―
Sorrento Therapeutics
―
Editas Medicine
―
Best Analysts Covering BNTC
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+37.99%
reiterated a buy rating 8 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +37.99% per trade.
---